Chimeric antigen receptor T (CAR-T) cell therapy is a promising and precise targeted
therapy for cancer that has demonstrated notable potential in clinical applications. However …

Chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of
hematologic malignancies. Approximately half of patients with refractory large B cell …

Genome editing technologies hold great promise for numerous applications including the
understanding of cellular and disease mechanisms and the development of gene and …

Chimeric antigen receptor (CAR) T-cell therapy targeting T-cell acute lymphoblastic
leukemia (T-ALL) faces limitations such as antigen selection and limited T-cell persistence …

Current chimeric antigen receptor-modified (CAR) T-cell products are evaluated in bulk,
without assessing functional heterogeneity. We therefore generated a comprehensive single …

Purpose CAR-T cell therapy has proven to be a disruptive treatment in the hematology field,
however, less than 50% of patients maintain long-term response and early predictors of …

Population aging, a pervasive global demographic trend, is anticipated to challenge health
and social systems worldwide. This phenomenon is due to medical advancements enabling …

Under compassionate use, chimeric antigen receptor (CAR) T cells have elicited durable
remissions in patients with refractory idiopathic inflammatory myopathies (IIMs). Here, we …

Chimeric antigen receptor (CAR) T cell (CAR-T) therapy has emerged as a revolutionary
cancer treatment modality, particularly in children and young adults with B cell malignancies …

CD19-specific chimeric antigen receptor (CAR) T cell therapy has changed the treatment
paradigm for pediatric, adolescent and young adult (AYA) patients with relapsed/refractory B …